Europe - Euronext Brussels - EBR:UCB - BE0003739530 - Common Stock
UCB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. UCB has only an average score on both its financial health and profitability. UCB is valued quite expensive, but it does show an excellent growth. This makes UCB very considerable for growth investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 5.52 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 39.45 | ||
| Fwd PE | 24.63 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.58 | ||
| EV/EBITDA | 20.94 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.
ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UCB.BR). This can be considered as Overvalued.
UCB SA (UCB.BR) has a profitability rating of 6 / 10.
The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 39.45 and the Price/Book (PB) ratio is 5.09.
The Earnings per Share (EPS) of UCB SA (UCB.BR) is expected to grow by 60.25% in the next year.